Literature DB >> 23697553

Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?

Catharina De Schauwer1, Gerlinde R Van de Walle, Ann Van Soom, Evelyne Meyer.   

Abstract

In the past decade, mesenchymal stem cells (MSC) have received much attention in equine veterinary medicine. The first therapeutic use of equine MSC was reported in 2003. Since then, the clinical application of MSC has been exploding with thousands of horses now treated worldwide. At present, MSC are mainly used in veterinary medicine to treat musculoskeletal diseases based on their ability to differentiate into various tissues of mesodermal origin. This is in marked contrast to human medicine, where MSC therapies are primarily focused on immune-mediated, inflammatory, and ischemic diseases. In this review, both orthopedic as well as non-orthopedic clinical applications of equine MSC are discussed. A brief overview is provided on the potential of MSC for non-orthopedic injuries with emphasis on those diseases, which occur in both humans and horses.

Entities:  

Mesh:

Year:  2013        PMID: 23697553     DOI: 10.1080/01652176.2013.800250

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  17 in total

1.  Peripheral Blood-Derived Mesenchymal Stromal Cells Promote Angiogenesis via Paracrine Stimulation of Vascular Endothelial Growth Factor Secretion in the Equine Model.

Authors:  Leen Bussche; Gerlinde R Van de Walle
Journal:  Stem Cells Transl Med       Date:  2014-10-13       Impact factor: 6.940

Review 2.  Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders.

Authors:  Mohamad Al Naem; Lynda Bourebaba; Katarzyna Kucharczyk; Michael Röcken; Krzysztof Marycz
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

3.  Regenerative therapy for the management of a large skin wound in a dog.

Authors:  Elena Zubin; Virna Conti; Fabio Leonardi; Stefano Zanichelli; Roberto Ramoni; Stefano Grolli
Journal:  Clin Case Rep       Date:  2015-05-26

4.  Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.

Authors:  Lynn M Pezzanite; Lisa A Fortier; Douglas F Antczak; Jennifer M Cassano; Margaret M Brosnahan; Donald Miller; Lauren V Schnabel
Journal:  Stem Cell Res Ther       Date:  2015-04-12       Impact factor: 6.832

Review 5.  Strategies of tenogenic differentiation of equine stem cells for tendon repair: current status and challenges.

Authors:  Asiyeh Shojaee; Abbas Parham
Journal:  Stem Cell Res Ther       Date:  2019-06-18       Impact factor: 6.832

Review 6.  Adipose-Derived Stromal/Stem Cells from Large Animal Models: from Basic to Applied Science.

Authors:  Joanna Bukowska; Anna Zuzanna Szóstek-Mioduchowska; Marta Kopcewicz; Katarzyna Walendzik; Sylwia Machcińska; Barbara Gawrońska-Kozak
Journal:  Stem Cell Rev Rep       Date:  2020-10-06       Impact factor: 5.739

7.  Mesangiogenic Progenitor Cells Are Tissue Specific and Cannot Be Isolated From Adipose Tissue or Umbilical Cord Blood.

Authors:  Serena Barachini; Marina Montali; Francesca M Panvini; Vittoria Carnicelli; Gian Luca Gatti; Nicola Piolanti; Enrico Bonicoli; Michelangelo Scaglione; Gabriele Buda; Paolo D Parchi
Journal:  Front Cell Dev Biol       Date:  2021-07-05

8.  Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.

Authors:  Lauren V Schnabel; Lynn M Pezzanite; Douglas F Antczak; M Julia Bevilaqua Felippe; Lisa A Fortier
Journal:  Stem Cell Res Ther       Date:  2014-01-24       Impact factor: 6.832

9.  Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy.

Authors:  Krzysztof Marycz; Katarzyna Kornicka; Monika Marędziak; Paweł Golonka; Jakub Nicpoń
Journal:  J Cell Mol Med       Date:  2016-09-14       Impact factor: 5.310

10.  Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.

Authors:  Jennifer M Cassano; Lauren V Schnabel; Margaret B Goodale; Lisa A Fortier
Journal:  Stem Cell Res Ther       Date:  2018-04-03       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.